Mental or Behavioral Dysfunction

METiS BioTech Announces China’s First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

2 days ago talkbio0Tagged AiTEM, biotech, China, Clinical, Drug Formulation Process, Metis people, nanodelivery, PBA, Phase III, pseudobulbar, Pseudobulbar affect

METiS BioTech; AI; drug formulation; Phase III; pseudobulbar affect (PBA); China; nanodelivery; AiTEM; clinical milestone

Alector’s GSK-partnered dementia drug latozinemab fails in late-stage trial

4 days ago talkbio0Tagged Alector, Clinical trial failure, Drug Development, Latozinemab, Phase 3 trial, Pick Disease of the Brain, Presenile dementia, Progranulins, SmithKline Beecham

Alector; GSK; latozinemab; dementia; frontotemporal dementia; Phase 3 trial; clinical trial failure; progranulin; drug development

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

4 days ago talkbio0Tagged AFFIRM-1 phase 3 trial, BNC210, Clinical trial failure, Discontinuation (procedure), Merck, Neuphoria, Neuroscience discipline, Partnership, Phobia, Social, Post-Traumatic Stress Disorder, Programs - Publication Format, Schizophrenia

Neuphoria Therapeutics; BNC210; social anxiety disorder; AFFIRM-1 phase 3 trial; clinical trial failure; program discontinuation; PTSD; Merck partnership; Minerva Neurosciences; schizophrenia therapy

Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued

5 days ago talkbio0Tagged AFFIRM-1, BNC210, Clinical Failure, Neuphoria, Phobia, Social, Post-Traumatic Stress Disorder, strategic review

Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD

Bicycle Health Grows Leadership Team to Expand Access for Justice-Involved Populations

2 weeks ago talkbio0Tagged Andy Thomas, Bicycle Health, Business Development, Criminal Justice, executive team, Leadership, Opioid Use Disorder, Steve Tomlin, virtual care

Bicycle Health; Leadership team; Executive team; Steve Tomlin; Business development; Criminal justice; Opioid use disorder; Virtual care; Manu Kuppalli; Andy Thomas

Somatix Readies Market Launch of First-of-its-Kind Wearable Medication Compliance Feature

2 weeks ago talkbio0Tagged Adherence To Medication Regime, AI-enabled, Detection, digital health, Gestures, partnering with, Presenile dementia, Preventive monitoring, Remote, Roche (company), SafeBeing platform, Somatix, Wearable Electronic Devices

Somatix; wearable technology; medication compliance; AI-enabled; gesture detection; remote patient monitoring; SafeBeing platform; dementia; partnering with Roche; digital health

FDA’s Move to Update GSK’s Leucovorin for Autism Raises Questions on Dose, Supply, and Data

1 month ago talkbio0Tagged Autistic Disorder, Clinical Data, Dosage, drug relabeling, leucovorin, Neurodegeneration Due To Cerebral Folate Transport Deficiency, SmithKline Beecham, United States Food and Drug Administration, Wellcovorin

FDA; GSK; leucovorin; Wellcovorin; autism; cerebral folate deficiency; drug relabeling; dose; supply; clinical data

FDA Rejects Lundbeck and Otsuka’s Rexulti for PTSD on Insufficient Efficacy Evidence

1 month ago talkbio0Tagged brexpiprazole, Clinical Trials, Complete, Drug Approval, Lundbeck, Otsuka, Post-Traumatic Stress Disorder, Response Letter, Rexulti, sertraline, sNDA, United States Food and Drug Administration

FDA; Rexulti; Lundbeck; Otsuka; PTSD; brexpiprazole; sertraline; Complete Response Letter; sNDA; clinical trials; drug approval

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

1 month ago talkbio0Tagged Antipsychotic Agents, Cholinergic Receptors, Cobenfy, drug price, launch, Myers, Nance-Horan syndrome, Prices, Schizophrenia, squibb, U.S., UK

Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026

Neurocrine Biosciences Reports Positive Phase 2 Results for Osavampator in Major Depressive Disorder

1 month ago talkbio0Tagged adjunctive treatment, AMPA-PAM, Biosciences, Clinical Research, Clinical Trials, Mental Depression, Neurocrine, osavampator, safety profile, SAVITRI

Neurocrine Biosciences; osavampator; Phase 2 results; major depressive disorder; AMPA-PAM; SAVITRI study; clinical trial; adjunctive treatment; depression; safety profile